ArticleScientific reports2026
Therapeutic potential and synergistic effects of antifungal and off target drugs against clinical isolates of Cryptococcus laurentii.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of Antimicrobial Activity, Toxicity, and Stability ofJournal of microbiology and biotechnology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cryptococcus laurentii is an emerging opportunistic yeast pathogen associated with unpredictable antifungal susceptibility and biofilm-mediated resistance. This study investigated the therapeutic potential and synergistic interactions of standard antifungals (fluconazole, amphotericin B) and off-target drugs against clinical isolates of C. laurentii. Three clinical isolates recovered from blood (n = 2) and cerebrospinal fluid (n = 1) were confirmed by phenotypic characteristics and PCR amplification of the 18 S rRNA gene (~ 480 bp). Biofilm formation was screened using Congo red agar and quantified via crystal violet assay. Susceptibility testing employed CLSI-guided disc/well diffusion and broth microdilution methods for antifungals and 14 off-target drugs. Minimum biofilm inhibitory concentrations (MBICs) were determined, and synergistic effects were evaluated using checkerboard assays (fractional inhibitory concentration index, FICI) in planktonic cells and biofilms, supplemented by coverslip biofilm reduction assay. Isolates showed moderate biofilm production (mean OD₅₉₅ = 0.32 ± 0.008), fluconazole susceptibility (mean MIC = 0.77 µg/mL), and amphotericin B resistance (mean MIC = 4.48 µg/mL). Diclofenac sodium exhibited the strongest off-target activity (mean MIC = 1.32 µg/mL). Checkerboard assays revealed synergy between fluconazole + amphotericin B (FICI = 0.5) and fluconazole + diclofenac sodium (FICI = 0.32) in planktonic cells, with additive effects against biofilms (FICI = 0.9). The fluconazole-diclofenac combination significantly disrupted biofilm matrix. Diclofenac sodium enhances fluconazole efficacy and disrupts biofilms, supporting drug repurposing as an adjuvant strategy for managing biofilm-associated C. laurentii infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.